| ID | 119038 |
| 著者 |
Ogawa, H
Yoshinogawa Hospital
板東, 浩
Yoshinogawa Hospital|Medical Research|Tokushima University|Japan Low Carbohydrate Diet Promotion Association
KAKEN研究者をさがす
Abe, T
Yoshinogawa Hospital
Nakanishi, M
Yoshinogawa Hospital
Watanabe, O
Yoshinogawa Hospital
|
| キーワード | Oral semaglutide (Rybelsus)
Type 2 diabetes (T2D)
Gastro Esophageal Reflux Disease (GERD)
Gastrointestinal adverse effects (GIAEs)
Sodium N-[8-(2-hydroxybenzoyl) amino] caprylate (SNAC)
|
| 資料タイプ |
学術雑誌論文
|
| 抄録 | Background: Oral semaglutide (Rybelsus) has been recently in focus for type 2 diabetes (T2D).
Case presentation: Case is 61-year-old female with T2D, obesity, fatty liver and Gastro Esophageal Reflux Disease (GERD). Her HbA1c was 13.2% in Dec 2021, and she started to have metformin, empagliflozin and Rybelsus from 3mg to 7mg/day. General situation was improved as -4.2% of HbA1c and -8kg in weight for 4 months. Discussion and Conclusion: This case has GERD, and then the doses of Rybelsus kept 7mg/day. She did not feel any gastrointestinal adverse effects (GIAEs). This impressive case will become reference for diabetic practice. |
| 掲載誌名 |
SunText Review of Medical & Clinical Research
|
| ISSN | 27664813
|
| 出版者 | SunText Reviews
|
| 巻 | 3
|
| 号 | 3
|
| 開始ページ | 162
|
| 発行日 | 2022-08-19
|
| 権利情報 | This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
|
| 出版社版DOI | |
| 出版社版URL | |
| フルテキストファイル | |
| 言語 |
eng
|
| 著者版フラグ |
出版社版
|
| 部局 |
医学系
病院
|
